BYAM REBECCA (Chief Financial Officer) purchased 1.8% of their position (10K shares) of HCW BIOLOGICS INC. on the open market
Open‑market purchase worth $20.7K — a small addition. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 9/13/2023ACC: 0001209191-23-049314
Officer· Chief Financial Officer
Since Jul 2021
+10K
Net shares
Net buyer
$20.7K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
10K acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+5K
Price / share
$2.05
Trade value
$10.27K
% of position
0.9%
9/11/2023
558.95K→563.95K
Common Stock
Direct
Shares
+5K
Price / share
$2.09
Trade value
$10.44K
% of position
0.9%
9/12/2023
563.95K→568.95K
Total
Net shares
+10K
Net value
$20.71K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/11/2023 | P · Purchase | +5K | $2.05 | $10.27K | 0.9% | 558.95K | 563.95K |
| Common Stock Direct | 9/12/2023 | P · Purchase | +5K | $2.09 | $10.44K | 0.9% | 563.95K | 568.95K |
| Total | +10K | $20.71K | ||||||
Derivative Transactions0
No derivative transactions reported